Evidence map›Paper›PMID 33467524›Full record

ReviewInternational journal of molecular sciences2021

Toll-Like Receptors in Acute Kidney Injury.

Cristina Vázquez-Carballo, Melania Guerrero-Hue, Cristina García-Caballero, Sandra Rayego-Mateos, Lucas Opazo-Ríos, José Luis Morgado-Pascual, Carmen Herencia-Bellido, Mercedes Vallejo-Mudarra, Isabel Cortegano, María Luisa Gaspar and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Anthraquinones fromDrug design, development and therapy · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Alkaline phosphatase treatment of acute kidney injury-an update.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Cristina Vázquez-CarballoRenal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.
Melania Guerrero-HueMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
Cristina García-CaballeroMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
Sandra Rayego-MateosRenal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.
Lucas Opazo-RíosRenal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.ORCID 0000-0003-3586-3319
José Luis Morgado-PascualMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
Carmen Herencia-BellidoRenal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.
Mercedes Vallejo-MudarraMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
Isabel CorteganoImmunobiology Department, Carlos III Health Institute, 28220 Majadahonda (Madrid), Spain.
María Luisa GasparImmunobiology Department, Carlos III Health Institute, 28220 Majadahonda (Madrid), Spain.
Belén de AndrésImmunobiology Department, Carlos III Health Institute, 28220 Majadahonda (Madrid), Spain.ORCID 0000-0002-7391-2823
Jesús EgidoRenal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, 28040 Madrid, Spain.
Juan Antonio MorenoMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.ORCID 0000-0002-7468-2871
Instituto Maimónides de Investigación Biomédica de Córdoba · ESInstituto de Salud Carlos III · ESUniversidad Autónoma de Madrid · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ES

Funding

Instituto de Salud Carlos III PI17/00130Instituto de Salud Carlos III PI20/00375
6 · The paper itself

Abstract

Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individuals/year. It is associated with increased mortality, mainly in low- and middle-income countries, where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes, including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic kidney disease. However, there are no specific treatments to decrease the adverse consequences of AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI, not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors (TLRs) are key regulators of the inflammatory response and have been associated to many cellular processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review, we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to this pathological condition.

Indexed as

Acute Kidney InjuryAnimalsDisease ProgressionHumansKidneyRenal Insufficiency, ChronicRenal Replacement TherapyRisk FactorsToll-Like Receptor 4Toll-Like ReceptorsToll-Like Receptor 4Toll-Like Receptorsacute kidney injurydrugsinflammationtherapytoll-like receptors

Identifiers

PMID33467524
PMCPMC7830297
OpenAlexW3118719461

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.